Physician- and PhD-authored articles from the Med Plug RX research library, grounded in the peer-reviewed literature — readable here, cited to source.
Twenty-three original articles, cited to primary source — written for physicians who verify before they adopt.
The Med Plug RX research library — physician- and PhD-authored articles grounded in the peer-reviewed literature, with citations spanning Int J Mol Sci, Stem Cell Res Ther, Blood, Front Immunol and others. Verified physician accounts may request the full text and primary citations behind any article.
A field survey of how leading practices are moving from cell-based therapies toward cell-free biologics — extracellular vesicles and exosome preparations — and why the shift is being driven by handling, consistency and documentation advantages rather than marketing.
A review of umbilical cord PRP-derived extracellular vesicles: why neonatal source tissue yields a richer growth-factor and anti-inflammatory cargo than adult peripheral blood, and how acellular nanoparticles cross biological barriers that whole cells cannot.
An examination of what published clinical research actually demonstrates about adult, non-embryonic stem cell self-renewal after introduction to a host — separating documented findings from the claims frequently made around them.
A comparative analysis of culture-expanded versus native cell populations: native preparations retain a more diverse cell population, while culturing acts as a selection pressure and each additional passage raises mutation risk — the trade-offs that drive screening and characterization requirements.
An analysis of mitochondrial function in umbilical cord-derived stem cells and why metabolic activity is emerging as a meaningful quality signal for regenerative preparations.
The science behind CytoCord: what the epithelial cell populations of the umbilical cord lining contribute, and why whole-tissue preparations preserve signaling relationships that isolated fractions lose.
The science behind ExCyte: the role extracellular vesicles play within platelet-rich plasma, and how vesicle content — not platelet count alone — drives the signaling profile of a PRP-derived preparation.
A primer on intercellular signaling — the ligands, receptors and vesicle-mediated pathways through which cells coordinate — written for physicians who want the mechanism, not the marketing.
A review of the developing research on mitochondrial transfer between mesenchymal stromal cells and damaged tissue — one of the more remarkable documented mechanisms in the MSC literature.
What is established about mesenchymal stromal cells resident in umbilical cord tissue and Wharton's jelly — the source material behind cord-derived preparations — as the field moves from academic theory into applied life science.
The discipline behind the vial — how compliant material is actually made, validated and released.
Cleanroom classification, equipment qualification, batch records, media fills and release authority — the working anatomy of a compliant facility.
Why validation is a different claim than testing, what each GxP framework governs, and the four questions that separate a documented operation from a marketed one.
Identity is not potency. A comparison of differentiation, immunopotency, secretome and matrix approaches — and why one readout is never enough.
Media composition changes proliferation, phenotype and the secretome itself. Serum variability, vesicle contamination and the case for defined formulations.
Why so much preclinical work fails to replicate, and the specific practices — authentication, powering, blinding, reporting — that produce durable results.
Where the discipline is moving, and what the wider field has already learned the hard way.
The exosome is already a nanoparticle. How nanoscale metrology made counting possible, and why scaffolds are signals rather than scenery.
One proved a modified cell can cure refractory disease. The other proved cellular identity is reversible. What each achieved, and what each still costs.
MSC therapy was tested against ARDS at unprecedented speed. The durable lesson concerns product heterogeneity more than the virus.
The same preparation is a licensed medicine in one jurisdiction and unavailable in another. How the major regimes diverge, and what physicians should filter on.
A field with an unusual ratio of announcement to durable result. What held, what dissolved, and where the discipline honestly stands.
The underlying biology, and the origin of the material itself.
Exosomes, microvesicles and apoptotic bodies differ by origin, not merely size. How cargo is selected, and why isolation method determines what you get.
Two stem cell populations, two distinct vesicle repertoires. What each does, and why cell-free preparations gained ground on living-cell products.
The cord and placenta are discarded within minutes of most deliveries. What is lost, what genuine consent requires, and why these ethics are unusually clean.
Verified physician accounts may request the full citation list behind any preparation — the peer-reviewed studies themselves, not summaries — along with per-lot certificates of analysis.
